1. "2005"
Formats
  1. Journal Article (1579)
  2. Meeting Abstract (692)
  3. Book Section (139)
  4. Conference Paper (22)
  5. Book Whole (10)
Groups
  1. Department of Medicine (687)
  2. Surgery (543)
  3. Sloan Kettering Institute Faculty (472)
  4. GSK Faculty (467)
  5. Solid Tumor Oncology Division (402)
  6. Survivorship Research (336)

More Groups

People
  1. Clifford Hudis (50)
  2. Howard Scher (50)
  3. David Klimstra (49)
  4. Mark Kris (44)
  5. Larry Norton (40)
  6. Murray Brennan (38)

More People

Years
  1. 2005 (2442)
Publications
  1. Journal of Clinical Oncology (234)
  2. Blood (112)
  3. Cancer Research (85)
  4. Modern Pathology (56)
  5. Clinical Cancer Research (50)
  6. International Journal of Radiation Oncology, Biology, Physics (49)

More Publications

Publishers
  1. American Society of Clinical Oncology (234)
  2. Elsevier Inc. (228)
  3. Springer (173)
  4. American Association for Cancer Research (143)
  5. Lippincott Williams & Wilkins (140)
  6. Nature Publishing Group (125)

More Publishers

Results (2442)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of fetal radiation dose during maternal sentinel lymph node mapping for breast cancer
    Meeting Abstract

    Montgomery, L.; Dauer, L.; Doddamane, I.; St. Germain, J.; Zanzonico, P.; Cody, H.; Borgen, P.; Divgi, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors
    Meeting Abstract

    Monk, J. P.; Calero-Villalona, M.; Dupont, J.; Larkin, J.; Otterson, G.; Spriggs, D.; Hannah, A. L.; Cropp, G. F.; Johnson, R. G.; Hensley, M. L.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Combination therapy with perifosine and temozolomide for glioma treatment: Preclinical trial using a mouse glioma model
    Meeting Abstract

    Momota, H.; Nerio, E.; Finney, J.; Lyustikman, Y.; Holland, E.
    Neuro-Oncology (2005)

    Fulltext@MSK | Save
  • Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma
    Meeting Abstract

    Molina, A. M.; Advani, R.; Reddy, S.; Hoppe, R.; Friedberg, J. W.; Sadan, S.; Myskowski, P.; Kim, Y. H.; Horwitz, S. M.
    Blood (2005)

    Fulltext@MSK | Save
  • Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Misbah, S. A.; Shaheen, P. E.; Elson, P. J.; Negrier, S.; Motzer, R. J.; Andresen, S. W.; Bukowski, R. M.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Palliative operations for symptoms caused by advanced cancer in the skin, superficial soft tissues and lymph nodes: A prospective outcomes analysis
    Meeting Abstract

    Miner, T. J.; Jaques, D. P.
    Annals of Surgical Oncology (2005)

    Fulltext@MSK | Save
  • Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Milton, D. T.; Kris, M. G.; Azzoli, C. G.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Milowsky, M. I.; Galsky, M.; Lewin, J.; Rozario, C. P.; Owens, L.; Marshall, T.; Nanus, D.; Webb, I. J.; Scher, H. I.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC
    Meeting Abstract

    Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Hussain, S.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100)
    Meeting Abstract

    Miller, K. D.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M. A.; Perez, E. A.; Shenkier, T. N.; Davidson, N. E.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save